This book aims to cover the applications of nanotechnology against human infectious diseases. The chapters of the book discuss the role of nanotechnology in the efficient diagnosis and treatment of these diseases. It explicitly provides an overview of nanodiagnostics for infectious diseases from nanoparticles-based, nanodevice-based, and point-of-care platforms. The book also covers the state-of-the-art review of recent progress in biomimetic and bioengineered nanotherapies to treat infectious diseases. It also presents a nano carrier-based CRISPR/Cas9 delivery system for gene editing and its applications for developing interventional approaches against communicable diseases. Further, it reviews the recent developments in nanotechnology to engineer nanoparticles with desired physicochemical properties as a line of defense against multi-drug resistance micro-organisms. Cutting across the disciplines, this book serves as a guide for researchers in biotechnology, parasitology, and nanotechnology.

This book aims to cover the applications of nanotechnology against human infectious diseases. The chapters of the book discuss the role of nanotechnology in the efficient diagnosis and treatment of these diseases. It explicitly provides an overview of nanodiagnostics for infectious diseases from nanoparticles-based, nanodevice-based, and point-of-care platforms. The book also covers the state-of-the-art review of recent progress in biomimetic and bioengineered nanotherapies to treat infectious diseases. It also presents a nano carrier-based CRISPR/Cas9 delivery system for gene editing and its applications for developing interventional approaches against communicable diseases. Further, it reviews the recent developments in nanotechnology to engineer nanoparticles with desired physicochemical properties as a line of defense against multi-drug resistance micro-organisms. Cutting across the disciplines, this book serves as a guide for researchers in biotechnology, parasitology, and nanotechnology.

This book examines applications of multi-omics approaches for understanding disease etiology, pathogenesis, host-pathogen interactions. It also analyzes the genetics, immunological and metabolic mechanisms underlying the infections. The book also explores genomics, transcriptomics, translational-omics, and metabolomics approaches to understand the pathogenesis and identify potential drug targets. It reviews the role of epigenetic reprogramming in shaping the host-pathogen interactions and presents bioinformatics application in the identification of drug targets. Further, it examines the potential applications of RNA sequencing and non-coding RNA profiling to identify the pathogenesis. Lastly, it offers the current challenges, technological advances, and prospects of using multi-omics technologies in infectious biology.

The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.

This book examines applications of multi-omics approaches for understanding disease etiology, pathogenesis, host-pathogen interactions. It also analyzes the genetics, immunological and metabolic mechanisms underlying the infections. The book also explores genomics, transcriptomics, translational-omics, and metabolomics approaches to understand the pathogenesis and identify potential drug targets. It reviews the role of epigenetic reprogramming in shaping the host-pathogen interactions and presents bioinformatics application in the identification of drug targets. Further, it examines the potential applications of RNA sequencing and non-coding RNA profiling to identify the pathogenesis. Lastly, it offers the current challenges, technological advances, and prospects of using multi-omics technologies in infectious biology.

The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.